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The ubiquitin-proteasome pathway in cancer
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Summary Degradation by the 26S proteasome of specific proteins that have been targeted by the ubiquitin pathway is the major intracellular
non-lysosomal proteolytic mechanism and is involved in a broad range of processes, such as cell cycle progression, antigen presentation and
control of gene expression. Recent work, reviewed here, has shown that this pathway is often the target of cancer-related deregulation and
can underlie processes, such as oncogenic transformation, tumour progression, escape from immune surveillance and drug resistance.
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Eukaryotic cells contain two major proteolytic pathways, namely
the lysosomal pathway, which mainly degrades extracellular
proteins that have entered the cell via endocytosis or pinocytosis,
and the non-lysosomal pathway, which degrades in a cellular
particle called the proteasome intracellular proteins, which have
been targeted for destruction by a protein called ubiquitin. The
ubiquitin-proteasome pathway was initially regarded as a simple
mechanism of destruction for old or damaged proteins, but it is
now emerging as a crucial mechanism in cellular regulation.
Indeed, in recent years it has been found that protein degradation
accounts for the regulation of proteins, such as cyclins, cyclin-
dependent kinase inhibitors, pS3, c-JUN and c-FOS, and it has
become increasingly clear that proteolysis is a mechanism ofregu-
lation ofmany cellular processes, including cell cycle progression,
transcriptional regulation and antigen presentation (Hochstrasser,
1995; King, 1996; Pahl and Baeuerle, 1996). The importance of
proteolysis probably stems from the advantages that it offers over
other regulation mechanisms, such as the rapidity ofthe reduction
of the cellular level of a specific protein and the irreversibility of
the loss of function after degradation. In addition, it has to be
stressed that, by degrading inhibitors or activators of the various
pathways, protein degradation can actboth as an up-regulation or a
down-regulation mechanism.
The ubiquitin-proteasome pathway degrades cytosolic and
nuclear proteins via an ATP- and ubiquitin-dependent mechanism,
which is centred on a multicatalytic proteinase complex called the
26S proteasome. Substrate proteins are targeted for degradation by
the addition of multiple monomers of ubiquitin, a 76 amino acid
polypeptide, to specific residues in a multi-step reaction requiring
three classes of enzymes called El, E2 and E3. Initially, a
ubiquitin-activating enzyme (El) activates a ubiquitin monomer at
its C-terminal glycine residue to a high-energy thiol ester inter-
mediate. Then, E2 enzymes, also known as ubiquitin-conjugating
enzymes (UBC), transfer ubiquitin from El to the substrate that is
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bound to a ubiquitin-protein ligase (E3). The first ubiquitin mole-
cule is usually bound to the substrate by an isopeptide bond
between the C-terminal glycine ofubiquitin and an E-NH2 group of
a lysine residue ofthe substrate. The polyubiquitin chain is formed
in multiple cycles of this reaction by addition of another ubiquitin
molecule to the lysine at position 48 of the previously already
conjugated ubiquitin. Release of ubiquitin from the isopeptide
linkage with the lysine residue is performed by isopeptidases called
ubiquitin C-terminal hydrolases (UCH). Their function is probably
important not only in recycling ubiquitin monomers after substrate
degradation but also in the recovery ofpoorly orincorrectly ubiqui-
tinated proteins (Shaeffer and Cohen, 1996).
Polyubiquitinated proteins are substrates for the 26S protea-
some. This consists of three large multi-subunit complexes,
namely a 700-kDa 20S proteasome core particle and two 19S cap
structures, also called PA 700 (for proteasome activator of 700
kDa) (reviewed in Peters, 1994). The 20S particle has the structure
of a hollow cylinder composed of four rings of seven related
subunits and containing a central channel with three cavities
(Lowe et al, 1995; Groll et al 1997). The inner rings are formed of
3-subunits, which carry the proteolytically active sites on the inner
surface. The outer rings contain subunits that lack proteolytic
activity and are thought to control the access to the central cavity.
The isolated 20S particle has very limited activity in vitro
compared with the 26S proteasome, which is formed by the 20S
proteasome with the addition of two 19S/PA700 substructures in
opposite orientations, one at each end (Peters et al, 1993), as
revealed by electron microscopy (Figure 1). The 19S regulatory
complex consists of at least 15 subunits, which can be classified
into ATPases and non-ATPases (Dubiel et al, 1995a), and is
thought to act in recognition, unfolding and translocation of the
substrates into the 20S proteasome for proteolysis (Rubin and
Finley, 1995). The composition and the function ofthe regulatory
complex is not yet fully characterized and recent data have shown,
forexample, that the regulatory complex also contains an isopepti-
dase capable ofdeubiquitinating substrates (Lam et al, 1997).
Because of the broad involvement of ubiquitin-proteasome
proteolysis in fundamental biochemical processes, this pathway is
a potential target for cancer-related deregulation, and alterations of
proteasome function have indeed been described in events, such as
cellular transformation by oncogenic viruses (Scheffner et al,
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Figure 1 (Adapted with permission from Rubin and Finley, 1995). The 26S
proteasome is a multiprotein complex that acts as a multicatalytic protease
degrading proteins that have been targeted by the ubiquitin pathway. Proteins
are ubiquitinated in a cascade reaction involving three classes of
ubiquitinating enzymes called El, E2 and E3 and can be deubiquitinated by
isopeptidases. The 20S proteasome consists of a stack of four rings of seven
subunits. The inner rings made of5-subunits display the catalytic sites on the
inner surface. At each end, the 20S proteasome can be capped by a
regulatory complex called 19S or PA700, which contains ATPases and is
probably involved in recognition, unfolding and translocation of the substrate
into the 20S proteasome (Rubin and Finley, 1995)
1990, 1993; Ciechanover et al, 1994) and immune escape (Restifo
et al, 1993; Sibille et al, 1995; Rotem Yehudar et al, 1996; Seliger
et al, 1996). Furthermore, alterations of proteasome activity in
tumour samples have been reported recently to confer in colon and
possibly breast cancer a phenotype ofclinical aggressiveness asso-
ciated with poor prognosis (Catzavelos et al, 1997; Loda et al,
1997; Porter et al, 1997). Finally, mutations of proteasome
subunits have been found to result in amultidrug resistance pheno-
type in fission yeast (Gordon et al, 1993, 1996), and we have
recently shown that this pathway of multidrug resistance is
conserved in mammalian cells (Spataro et al, 1997). Here, we
therefore review the rapidly increasing body of information on the
role ofproteolysis by the ubiquitin/proteasome pathway in various
fields ofcancer biology.
p53 AND HPV.RELATED MALIGNANCIES
The product of the tumour-suppressor gene p53 is an unstable
nuclearprotein with a half-life of20-35 min in normal cells. After
cellular stress or DNA damage, p53 is stabilized, leading to
growth arrest or apoptosis. The rise in p53 protein level is
detectable almost immediately after DNA damage, and the
absolute level of p53 protein and the duration of the response
depend on the nature of the damage (reviewed in Cox and Lane,
1995). This accumulation ofp53 is thought to occur mainly via the
down-regulation of its degradation by the ubiquitin-proteasome
pathway (Harris, 1996; Maki et al, 1996). Although, at present,
this supposition has not been experimentally confirmed, it is
supported by experimental data in a cell line containing a thermo-
labile El ubiquitin-activating enzyme, in which p53 accumulates
at the non-permissive temperature; this accumulation is prevented
by introduction of the wild-type El gene (Chowdary et al, 1994).
Interestingly, recent evidence suggests that p53 degradation is
stimulated by the product ofthe p53-activated MDM2 gene (Haupt
et al, 1997), providing the basis for a mechanism by which the
activation of p53 could be self-limiting. Further research on regu-
lation of p53 by proteolysis is clearly warranted because alter-
ations in this pathway can be functionally equivalent to p53
inactivation. This is well exemplified in the case of human papil-
loma virus (HPV)-related cancers. The oncogenicity of the human
papilloma virus, which is involved in the aetiology of the majority
of human anogenital carcinomas, is mediated by up-regulation of
p53 degradation by the ubiquitin-proteasome pathway. The E6
oncoprotein encoded by high-risk HPV (e.g. HPV-16, -18, -5 and
-8) binds to p53 and promotes its degradation by the proteasome
(Scheffner et al, 1990) - a property that is critical for immortaliza-
tion ofhuman cells by HPV. In contrast, low-risk HPV (e.g. HPV-
6 and -11) encode an E6 protein that does not bind to p53 and does
not promote its degradation. The formation of the E6-p53
complex requires a cellular E6-binding protein called E6-AP (E6-
associated protein) (Scheffner et al, 1993), which forms thiol ester
complexes with ubiquitin in the presence of enzymes of the E2
category, such as UBC4 (Rolfe et al, 1995) or E2-F1 (Ciechanover
et al, 1994). E6-AP acts as an E3 enzyme, which ubiquitinates
p53, leading to its rapid degradation by the 26S proteasome.
p27 AS A PROGNOSTIC FACTOR
Progression through the cell cycle is promoted by oscillation in the
activity of cyclin-dependent kinases (CDK), and proteolysis by
the ubiquitin-proteasome pathway regulates CDK activity by
degrading CDK activators and inhibitors. Furthermore, proteolysis
by the proteasome is crucial during mitosis in triggering the transi-
tion from metaphase to anaphase (reviewed in King, 1996). Among
the substrates for proteolysis in the cell cycle machinery, clinically
important data are emerging with regard to the CDK inhibitor p27.
p27 inhibits a wide variety of cyclin-CDK complexes in vitro and
its activity is up-regulated by cytokines, such as TGF-,B and by
cell-cell contact, linking extracellular signals to the cell cycle
(Polyak, 1994; Slingerland, 1994). Loss of contact inhibition and
of response to TGF-3 in transformed cells may imply an alteration
of function of p27 during oncogenesis, even though p27 mutations
in human tumours are extremely rare (Hunter and Pines, 1994;
Morosetti et al, 1995; Ferrando, 1996). Unlike p21, which is also a
member of the family of cip/kip CDK inhibitors acting in G1 and
appears to be regulated principally at the transcriptional level, p27
is critically regulated post-translationally by proteolysis by the
ubiquitin-proteasome pathway (Pagano et al, 1995; Hengst and
Reed, 1996). Recently, it has been found that low p27 protein levels
in common tumours, such as colorectal carcinomas and breast
cancer, are associated with a poor prognosis (Catzavelos et al,
1997; Loda et al, 1997; Porter et al, 1997). In both tumour types
(Catzavelos et al, 1997; Loda et al, 1997), comparison of immuno-
histochemical analysis and in situ hybridization showed a discor-
dance between p27 mRNA and protein levels, suggesting that, also
in tumours, p27 levels could be regulated post-translationally.
Moreover, in one ofthe studies, it was clearly shown that increased
proteasome-dependent degradation was responsible for low p27
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Table 1 Summary of settings in which the ubiquitin-proteasome pathway plays a role in cancer (see text for references)
Proteolysis Functional Biological
Substrate dysregulation effect effect Comment
p53 Increased p53 Inactivation Transformation Mediated by E6
in HPV-related oncoprotein of 'high-risk'
malignancies HPV
p27 Increased p27 Inactivation Tumour Unfavourable prognosis
progression in retrospective
studies in colon
and breast cancer
Cyclin Dl, E and B Decreased? Cyclin Dl, E or B Tumour Overexpression in tumour
overexpression progression cell lines and surgical
specimens, contribution of
decreased degradation?
MHC-1-restricted Decreased Defective Escape from Suggested by in vitro
antigen immune studies, preliminary
presentation surveillance in vivo evidence
NF-KB Increased Increased Resistance Overcome
inhibitor, NF-KB to TNF-a by proteasome
lIB activation killing inhibitors
Transcription Decreased Increased Multidrug Evidence in yeast, highly
factors of the AP-1 activity resistance conserved pathway
AP-1 family in human, role in tumour
drug resistance?
levels in tumour samples of colorectal carcinomas. Total cellular
extracts from frozen tumour samples were tested for p27 protea-
some-mediated degradation using recombinant p27 as a substrate,
and a very good correlation was found between low levels of p27
and increased proteasome activity. Degradation was abolished by
proteasome depletion and resumed after proteasome readdition
(Loda et al, 1997). Down-regulation ofp27 by the proteasome was
found in tumours regardless of clinical stage. In breast cancer,
Catzavelos et al (1997) showed that increased p27 proteolysis can
be an early event in tumorigenesis, as suggested by analysis of
high-grade ductal carcinoma in situ (DCIS) or, alternatively, can
occur upon progression, as shown by reducedp27 levels in axillary
lymph node metastasis compared with primary tumours assessed
simultaneously. Even taking into account the caveats associated
with retrospective studies on prognostic factors, these three recent
studies (Catzavelos et al, 1997; Loda et al, 1997; Porter et al, 1997)
conclude that p27 protein level (and its proteasome-dependent
degradation, which was shown tobeinversely related) arepowerful
independent prognostic factors of survival in both tumour types
and show clearly that deregulation of gene products involved in
clinical tumour progression can occur via alterations ofubiquitin-
proteasome proteolysis. Furthermore, they show that this is not a
rare event, given that the unfavourable phenotype of decreased
p27 levels (defined as immunostaining in < 50% of the cells or as
a score of staining of 0-1 on a 0 to 6 scale) involves the majority
of the studied population for both colorectal cancer and breast
cancer (Catzavelos et al, 1997; Loda et al, 1997; Porter et al, 1997).
Thus the frequency of the phenotype of decreased p27 and its
distribution, which is independent ofmost otherprognostic factors,
make p27 levels a very promising new prognostic factor to be eval-
uated further. Loda et al (1997) have shown that, perhaps
unexpectedly, p27 degradation activity is notcorrelated with degra-
dation by the proteasome of other substrates, such as p21 and
cyclin A, which underscores that the substrate specificity of the
ubiquitin-proteasome pathway is highly regulated (Hochstrasser,
1995). Identification ofthe element(s) responsible fortargeting p27
to the ubiquitin-proteasome pathway would, of course, be
extremely important for unravelling this novel pathway associated
with tumourprogression.
Like p27, other elements of the cell cycle machinery that are
substrates of ubiquitin-proteasome degradation are potential
targets for deregulation in tumours. One of the best characterized
transitions in the normal cell cycle is the rapid proteasome-medi-
ated degradation ofcyclin B at the exit from mitosis (Glotzer et al,
1991), and recent evidence shows that continuing rapid proteolysis
accounts for the low levels of cyclin B until the onset of S phase
(Amon etal, 1994; Brandeis, 1996). Cyclin B has been found to be
overexpressed in a set of breast cancer cell lines (Keyomarsi and
Pardee, 1993), and it would be interesting to assess whether or not
decreased proteolysis by the proteasome is involved in its overex-
pression. Similarly, cyclin E has been found to be overexpressed in
breast cancercell lines and in surgical specimens ofbreast tumours
(Keyomarsi et al, 1994, 1995), and cyclin Dl is frequently overex-
pressed in many common tumour types (Betticher, 1996). Recent
evidence suggests that cyclin DI and E are substrates of the
ubiquitin-proteasome pathway (Clurman et al, 1996; Diehl et al,
1997), and decreases in their degradation could contribute to the
overexpression ofthese cyclins in tumours.
ANTIGEN PRESENTATION
The 26S proteasome is responsible for the processing of MHC-
restricted class I antigens. Peptides derived from endogenously
expressed cytoplasmic proteins are carried by MHC class I mole-
cules from theendoplasmic reticulum to the surface forrecognition
by cytotoxic T lymphocytes. The proteasome was postulated to be
theproteolytic system thatdegrades cytosolic proteins, when it was
found that the genes encoding subunits LMP-2 and LMP-7 of the
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proteasome complex were included in the MHC gene cluster (see
forexample Beck et al, 1992). Experimentsperformed in a mutant
cell with athermolabileEl-ubiquitinating enzyme (Michalek et al,
1993) and with proteasome inhibitors (Rocketal, 1994; Cerundolo
etal, 1997) have subsequently demonstrated that theproteasome is
necessary for class I-restricted antigen presentation. This is
confirmed by the analysis of mice lacking LMP-7, which have
decreased surface expression of MHC class I molecules and
presentantigens inefficiently (Fehling et al, 1994). It has also been
shown that 3 of the 28 subunits composing the 20S catalytic core,
namely subunits X, Y and Z, are interchangeable with the alterna-
tive subunits LMP2, LMP7 and LMP1O respectively (Belich et al,
1994; Fruh et al, 1994; Groettrup et al, 1996; Hisamatsu et al,
1996; Nandi et al, 1996) upon induction by interferon-y. These
substitutions result in an enhancement of peptidase activity, a
change in thequality ofgeneratedpeptides(Gaczynska etal, 1996;
Kuckelkorn et al, 1995) and eventually in a more efficient antigen
presentation. Interferon-y also induces the binding to the 20S
catalytic core ofthe proteasome of acomplex called 11S regulator
or PA28, which may further increase the spectrum of peptides
generated (Groettrup et al, 1995). There is strong evidence that
MHC class I-restrictedpeptidepresentation is modified in tumours
and may contribute to escape from immune surveillance.
Alterations of ubiquitin-proteasome degradation have been
reported among other alterations in this pathway. Three different
small-cell lung carcinoma lines with low to undetectable levels of
mRNA forLMP2 and LMP7 and functional deficiencies in antigen
presentation have been described (Restifo et al, 1993). The mouse
T-cell lymphoma line SP-3 displays underexpression of LMP-2
and is defective for antigen presentation, whereas LMP-2 expres-
sion and antigen presentation to cytotoxic T lymphocytes are
restored upon expression ofinterferon-yby transfection (Sibille et
al, 1995). Similar studies on tumour samples are rare. An analysis
of expression of both LMP-2 and LMP-7 proteasome subunits
together with other elements oftheantigenpresentationmachinery
has been carried out on a primary renal cancer and a lymph node
metastasis of the same patient and compared with normal kidney.
Deficiencies at all levels, including the expression of LMP-2 and
LMP-7 proteasome subunits, were associated with transformation
andprogression. Interferon-a and, in particular, interferon-y could
partly suppress these defects (Seliger et al, 1996). The potential
importance of subunits LMP-2 and LMP-7 for MHC class I-
restricted antigen presentation is also underscored by the fact that
they are specifically down-regulated after viral transformation in
vitroby oncogenic viruses (Rotem Yehudar etal, 1996).
REGULATION OF TRANSCRIPTION FACTORS BY
PROTEOLYSIS
Increasing evidence shows that the proteasome also participates in
events thatcontrol genetranscription. Severaltranscriptional regu-
lators,including nuclearfactor-kappa B (NF-KB),p53 (seeabove),
c-JUN, sterol-regulated element-binding proteins and MATa2
have beenrecently shown to be regulatedby proteolysis, either for
the activation or the inactivation of gene expression (for a review
see Pahl and Baeuerle, 1996).
NF-KB is involved in the activation ofgenes encoding products
such as cytokines, chemokines, growth factors, cell-adhesion
molecules and surface receptors in response to a great-variety of
pathogenic signals and therefore has a central role inmediating the
immune/inflammatory responses. NF-KB has been reported to be
activated by the cytotoxic agents TNF-a, daunorubicin, etoposide,
ionizing radiation or oxidative stress but not by the protein kinase
C inhibitor staurosporine (Wang etal, 1996). The activation ofNF-
KB requires two steps of proteasome-dependent proteolysis.
Active NF-KB is a nuclear heterodimer consisting oftwo subunits
called p50 and p65. Ubiquitin-proteasome proteolysis is involved
first in the biogenesis ofthe subunit p50 from the precursor p105
and then in the cytoplasmic degradation of the inhibitory factor
IKB, which allows the translocation of the active dimer into the
nucleus (Palombella et al, 1994). Recently published data attribute
an anti-apoptotic role to NF-KB in response to some cytotoxic
agents (Beg and Baltimore, 1996; Van Antwerp et al, 1996; Wang
et al, 1996). In one case, TNF-a was more toxic for immortalized
embryonic cells of NF-KB knock-out mice than for controls (Beg
and Baltimore, 1996) and in other experiments expression of the
super-repressor IKB-a (inhibiting NF-KB activation) moderately
increased the sensitivity to TNF-a, daunorubicin and ionizing
radiation (Wang et al, 1996). Consistent with this, the proteasome
inhibitor MG132 (preventing NF-KB activation) strongly
enhanced, in a dose-dependent fashion, the killing of HT1080V
cells by TNF-a. The proto-oncogene products c-JUN and c-FOS
constitute the transcription factor AP-1 (for activator protein 1)
either as heterodimers or as c-JUN homodimers and are well-
known substrates for ubiquitin-proteasome degradation (Treier et
al, 1994; Jariel Encontre et al, 1995; Tsurumi et al, 1995a;
Hermida Matsumoto et al, 1996; Musti et al, 1997). The degrada-
tion ofc-JUN is dependent on a segment of27 amino acids called
the delta domain, which is necessary for both ubiquitination and
degradation. The deltaregion, and hence this mechanism ofdown-
regulation, is lostin v-JUN, the transforming retroviral counterpart
ofc-JUN, and this increased stability very likely contributes to its
oncogenicity (Treier et al, 1994). Moreover, it has been convinc-
ingly shown that c-JUN is degraded by this pathway, but recent
data suggest that ubiquitin-proteasome-mediated proteolysis ofc-
JUN could play an essential role in regulation ofactivity of AP-1
factors (Musti et al, 1997). There is a high degree ofregulation of
c-JUN proteolysis, with the presence of c-FOS and dimerization
itself influencing the ubiquitination and the degradation activity
(Tsurumi et al, 1995a; Hermida Matsumoto et al, 1996). Like NF-
KB, AP-1 factors are important in the cellular response to oxida-
tive stress (Schreiber et al, 1995; Pinkus et al, 1996) and are
involved in the induction ofa variety ofgenes encoding important
enzymes in glutathione-related detoxification pathways, such as
the isozymes a, zt and y of glutathione-S-transferase and y-
glutamyl-cysteine synthetase. Up-regulation of AP-1 activity has
been associated with drug resistance in several instances, such as
in a multidrug-resistant derivative of MCF7 cells obtained after
vincristine selection (Moffat et al, 1994) in etoposide-resistant
human leukaemia cell lines (Ritke et al, 1994) and in cisplatin-
resistant ovarian cancer lines (Yao et al, 1995). Given the rele-
vance ofproteolysis for c-JUN regulation, this acquires particular
importance in the light of recent data discussed in the following
section that link the proteasome, AP-1 factors and multidrug resis-
tance (Spataro et al, 1997).
DRUG RESISTANCE
We recently identified a novel component of the 26S proteasome
that indicates a link between ubiquitin-dependent proteolysis and
drug resistance. Overexpression of the fission yeast Padl protein
confers multidrug resistance to unrelated compounds, such as
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staurosporine, caffeine andleptomycin B, through the activation of
the yeast transcription factor Pap1, a homologue of human AP-1
(Shimanuki etal, 1995). Because studies in yeast mayhelp to iden-
tify important novel mechanisms in mammaliancells, we set out to
examine the role of a Pad1 human homologue. We have cloned the
human homologue of Padl (named POHI for Pad One Homo-
logue) and have shown by transfection experiments that its overex-
pression in mammalian cells can confer multidrug resistance to
7-hydroxystaurosporine, paclitaxel, doxorubicin and to ultraviolet
radiation. Interestingly, the amino acid sequence of POHI
displayed a significant similarity to the subunit S12/p4O ofthe 26S
proteasome (Dubiel et al, 1995b; Tsurumi et al, 1995b), and the
pattern of mRNA tissue expression was very similar to that previ-
ously described for other subunits ofthe 26S proteasome (Tsurumi
et al, 1995b). We demonstrated that POHI is in fact a novel
subunit of the 26S proteasome, as it co-purifies with proteasome
immunoprecipitates and with full 26S proteasomes obtained by
biochemical fractionation (Spataro et al, 1997). POHI also has a
significant sequence similarity with JAB1, which has been shown
to interact with c-JUN and to activate AP-1 transcription factors
(Claret et al, 1996). Various independent data, namely the depen-
dence of the padl multidrug resistance phenotype in fission yeast
on the activation of an AP-1 like factor, the sequence similarity
between POH1 and JAB1 and the importance of proteasome
degradation for c-JUN regulation support a model whereby over-
expression of the novel proteasome subunit POH1 could up-regu-
late AP-1 factors, resulting ultimately in drug resistance. Our data
show that POH1 overexpression does not activate P-glycoprotein
expression and does not alter intracellular accumulation of doxo-
rubicin. Nevertheless, it is not clear at this stage if the survival
advantage confered by POHI overexpression reflects a decreased
propensity for cell death or an alteration in the processing of
potentially lethal damage. POHI is widely expressed in human
tumour cell lines and work in progress is assessing its contribution
to tumour drug resistance. Interestingly, in recent years, two other
subunits of the 19S regulatory complex of the proteasome called
Mts2 and Mts3 have been identified in fission yeast through a
screen for mutants resistant to the mitotic spindle poison carben-
dazim (MBC) (Gordon et al, 1993, 1996). Thus, the 26S protea-
some plays an important role in determining multidrug resistance
in fission yeast. This pathway is highly conserved in mammals,
can confer drug resistance to anti-cancer agents in vitro and could
potentially be involved in drug resistance in human tumours. A
human homologue of another fission yeast gene called Crml,
which is involved like Pad1/POHl in Papl/AP-1-dependent
multidrug resistance (Toda et al, 1992; Kumada et al, 1996) has
been recently cloned (Fornerod et al, 1997). Interestingly, its
protein product interacts with the DEK-CAN fusion protein of
AML with the chromosomal translocation t(6;9), which is associ-
ated with poor prognosis (Lillington et al, 1993). It is possible that
proteasome/AP-1-mediated drug resistance contributes to the
dismal prognosis of this uncommon subset of acute myeloid
leukaemia (AML).
OTHER AREAS OF CANCER BIOLOGY
Among other areas of cancer biology in which involvement of the
ubiquitin-26S proteasome pathway may be relevant, growth factor
receptors and their signalling pathways should not be overlooked.
Several cell-surface receptors have been shown to be ubiquiti-
nated, suggesting that proteasome-mediated proteolysis could be
involved in their turnover (for a list see Ciechanover, 1994).
Involvement of proteasomes in the degradation of cell surface
receptors might have an increasing relevance in cancer
chemotherapy, as new agents that modulate growth factors and
their signalling pathways are developed. For example, there is
strong evidence for an involvement of the ubiquitin-proteasome
pathway in the degradation of tyrosine kinase receptors, such as
insulin-like growth factor receptors and epidermal growth factor
receptors. Of interest, it has been shown recently that herbimycin
A, which targets tyrosine-kinase-activated signal transduction by
inhibiting multiple tyrosine protein kinases and has in vitro and in
vivo anti-tumour activity, acts through an enhancement ofreceptor
degradation by the proteasome (Sepp Lorenzino et al, 1995).
Similar data have also been found with regard to the partly agonist
protein kinase C (PKC) inhibitor bryostatin 1 (Philip and Harris,
1995), which after transient activation down-regulates PKC
through the promotion ofits degradation by the proteasome (Lee et
al, 1996). Proteasome inhibitors have been shown to counteract the
effects ofherbimycin A in vitro (Sepp Lorenzino et al, 1995), and
it is conceivable that modulation of proteasome function might
influence the anti-tumour activity ofthese new classes ofdrugs.
Other cell surface receptors that are potential targets for protea-
some degradation are the T-cell antigen receptor (TCR) and the
platelet-derived growth factor (PDGF) receptor. One T-cell
receptor subunit is ubiquitinated on its cytoplasmic domain when
the receptor is occupied (Hou et al, 1994), but data are lacking on
possible effects on its function. The PDGF receptor-,3 also under-
goes polyubiquitination as a consequence of ligand binding and,
recent data suggest that the proteasome is responsible for the
degradation ofthe ligand-activated receptor (Mori et al, 1995).
DNA repair is another important area in which the
ubiquitin-proteasome pathway is potentially involved. The first
data supporting this notion came from budding yeast S. cerevisiae,
in which the rad6 DNA repair mutant is defective in the ubiquitin-
conjugating enzyme (E2) UBC2 and, intriguingly, the DNA repair
gene RAD23 encodes a protein containing a ubiquitin-like domain,
which is essential to its function (Watkins et al, 1993) and is
conserved in the human homologue HHR23B (Masutani et al,
1994). More recently, experiments performed on a ts mutant from
the mouse mammary carcinoma line FM3A, which contains a
thermosensitive ubiquitin-activating enzyme (El) have shown that
El mutants incubated at the restrictive temperature after UV expo-
sure display a decrease in clonogenic survival and defects in an
assay measuring DNA repair by the appearance of UV-induced
mutations (Ikehata etal, 1997). These data support acontribution of
ubiquitinconjugation to DNA repair in mammalian cells. However,
it remains to be seen ifthere is a true contribution to DNA repair of
the entire pathway of ubiquitin-proteasome-mediated proteolysis
or if, alternatively, ubiquitin-binding proteins, such as El or E2
enzymes, may have a direct influence on DNA repairby physically
interacting with DNA repair proteins carrying ubiquitin-like
domains, such as RAD23/HHR23B. Another area where intriguing
data await further elucidation is the potential role of deubiquiti-
nating enzymes in oncogenic transformation, as the yeast DOA4
isopeptidase is related to the product ofthe human Tre-2, which has
been found to be tumorigenic when expressed at high levels (Papa
and Hochstrasser, 1993); in addition, the human homologue of the
murine ubiquitin-releasing enzyme unp has been found to be over-
expressed in lung cancer cell lines (Gray et al, 1995).
Recently, ubiquitin-proteasome-mediated proteolysis has also
been found to have an important role in apoptosis ofnerve growth
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factor-deprived neurons (Sadoul et al, 1996), and it will be impor-
tant to investigate proteasome involvement in apoptosis induced
by anti-cancer drugs. Finally, it has recently been shown that
expression of heat shock protein 70 (hsp70), which is involved in
stress response and might have a role in drug resistance (Ciocca et
al, 1992), is induced up to 30-fold by a proteasome inhibitor,
unlike other members ofthe hsp family (Zhou et al, 1996).
DRUGS ACTING ON THE PROTEASOME
Pharmacological intervention to modulate one or several protea-
some functions could be therapeutically advantageous. There is
considerable interest in this possibility in the field ofimmunology,
in which the intent is to target activation by the proteasome ofNF-
KB, which has a key role in mediating the inflammatory and
immune response. The best known proteasome inhibitor is lacta-
cystin, a Streptomyces metabolite discovered on the basis of its
ability to induce neurite outgrowth in the Neuro 2A mouse neuro-
blastoma cell line (Fenteany et al, 1994). This inhibitor was subse-
quently shown to covalently modify a critical threonine residue of
the subunit X/MB1 of the proteasome core (Fenteany, 1995).
Lactacystin was found to inhibit cell cycle progression in human
osteosarcoma cells (Fenteany et al, 1994) and to induce apoptosis
in human monoblast cells (Imajoh Ohmi et al, 1995). However, we
are not aware ofany data on the anti-tumouractivity oflactacystin.
Interestingly, the clinically used anti-tumour drug aclacinomycin
A or aclarubicin, known as a DNA-intercalative agent, has been
shown to inhibit the degradation ofubiquitinated protein by selec-
tively inhibiting the chymotrypsin-like activity of the proteasome
(Figueiredo Pereira et al, 1996). It is not clear whether this could
contribute to the anti-tumour activity of this drug. Apart from
lactacystin, most ofthe proteasome inhibitors developed so far are
synthetic protease inhibitors of the family of peptidyl aldehydes
(Rock et al, 1994). Some of them, such as n-acetyl-leucinyl-
leucinyl-norleucinal (ALLN) and benzyloxycarbonyl (Z)-
leucinyl-leucinyl-leucinal (ZLLL) are cell penetrating, display
proteasome specificity and have been reported to induce apoptosis
in human tumour cell lines (Fujita et al, 1996; Shinohara et al,
1996). Because of the broad involvement of proteasomes in
normal cellular physiology, any attempt to target the proteasome
non-specifically might be associated with prohibitive in vivo
toxicity. However, the complexity and specificity of proteasome
regulation indicate that specific inhibitors of individual protea-
some-mediated processes might ultimately become available.
Moreover, the rapidly expanding knowledge about the role of
proteasomes in normal and tumour cells could provide in the
future a rational basis for the use ofproteasome-targeting drugs.
CONCLUSIONS
The ubiquitin-proteasome pathway clearly represents an impor-
tant area of research in cancer biology, although it has previously
been relatively neglected. Basic research has provided in recent
years an increasing body of information on the extent of the
involvement of this pathway in critical cellular processes, such as
cell cycle progression and regulation of gene expression. To date,
research has found that deregulation ofthis pathway in cancer can
be responsible for crucial phenomena, such as oncogenic transfor-
mation in HPV-related malignancies, poor prognosis in colorectal
and breast carcinoma, and that it is clearly involved in modulating
response to anti-cancer drugs. Understanding the complexity of
the ubiquitin-proteasome pathway, and in particular how the
specificity for a given substrate is regulated, should allow us in the
future to translate this knowledge into new therapeutic strategies.
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